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Edited by C. KalodimosAbstractLegend: The 13 residues at the extreme C-terminus of the
J-protein Zuo1 are sufficient for activation of the transcrip-
tion factor Pdr1. Key hydrophobic residues are seques-
tered within an autoinhibitory four-helix bundle,
necessitating unfolding of the C-terminal domain of Zuo1
for Pdr1 activation.The C-terminal 69 residues of the J-protein Zuo1 are
sufficient to activate Pdr1, a transcription factor
involved in both pleiotropic drug resistance and growth
control. Little is understood about the pathway of
activation by this primarily ribosome associated Hsp40
co-chaperone. Here, we report that only the C-terminal
13 residues of Zuo1 are required for activation of Pdr1,
with hydrophobic residues being critical for activity.
Two-hybrid interaction experiments suggest that the
interaction between this 13-residue Zuo1 peptide and
Pdr1 is direct, analogous to the activation of Pdr1 by
xenobiotics.However, simply dissociationof Zuo1 from
the ribosome is not sufficient for induction of Pdr1
transcriptional activity, as the C-terminal 86 residues of
Zuo1 fold into an autoinhibitory left-handed four-helix
bundle. Hydrophobic residues critical for interaction
with Pdr1 are sequestered within the structure of this
C-terminal domain (CTD), necessitating unfolding for
activation. Thus, although expression of the CTD does
not result in activation, alterations that destabilize the
structure cause induction of pleiotropic drug resis-
tance. These destabilizing alterations also result in
dissociationof the full-lengthprotein from the ribosome.
Thus, our results are consistent with an activation
pathway inwhich unfolding of Zuo1'sC-terminal helical
bundle domain results in ribosome dissociation fol-
lowed by activation of Pdr1 via a direct interaction.
© 2012 Elsevier Ltd. Open access under CC BY-NC-ND license. 0022-2836 © 2012 Elsevier Ltd. Open access under CC BY-NC-ND lice J. Mol. Biol. (2013) 425, 19–31nse. 
20 Unfolding of the C-Terminal Domain of Zuo1Introduction
The eukaryote-specific J-protein Zuo1 is an Hsp70
co-chaperone that is primarily associated with ribo-
somes andwidely accepted to play an important role in
the folding of nascent polypeptides.1–3 However,
evidence from several organisms indicates that Zuo1
also has a direct role in transcriptional regulation.4,5 In
Saccharomyces cerevisiae, Zuo1 has been identified
as an activator of the zinc cluster transcription factor
(TF) Pdr1.6,7 Zuo1 is a 433-amino-acid protein;
however, the 69 residues at Zuo1's C-terminus
(Zuo1365–433) are sufficient to activate Pdr1-dependent
transcription6,7 (Fig. 1a). The remainder of the protein
contains regions, such as the J-domain, known to be
important for its ribosome-associated role in protein
folding.2,3,8 Particularly relevant to this report, the
segment adjacent to the Pdr1-activating region is a
positively charged RNA-binding region necessary for
association with the ribosome.
Pdr1, like many TFs, has a C-terminal activation
domain that has minimal activity until activated by a
specific signal.9,10 Activation of Pdr1 by either Zuo1 or
a variety of xenobiotics initiates a highly specific
transcriptional response, upregulating a set of genes
belonging to the pleiotropic drug resistance (PDR)
regulon.6,11,12 Pdr1 target genes include ATP-binding(a) (c
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DNA encoding the indicated Zuo1 variants were spotted onto mcassette transporters, such as Pdr5 and Snq2. These
transporters extrude xenobiotics from cells, rendering
them resistant to a variety of toxic compounds.13,14
Evidence indicates that the PDR pathway also
functions in growth regulation, perhaps by extruding
small molecules sensed by neighboring cells.6,15
Pdr1 is constitutively bound toDNAandnot known to
shuttle between the nucleus and cytosol.16–18 The C-
terminusof Zuo1 interactswithPdr1 in yeast two-hybrid
assays, suggesting that Zuo1 activates Pdr1 directly.6
Since Zuo1 is primarily associated with the ribosome,
this localization raises the question of the pathway of
activation. Here, we report that the C-terminal domain
(CTD) of Zuo1 formsanautoinhibitory four-helix bundle
sequestering residues critical for Pdr1 activation.
Unfolding of the CTD causes both dissociation of
Zuo1 from the ribosome and release of autoinhibition
necessary for PDR activation.
Results
Dissociation of Zuo1 from the ribosome is not
sufficient for Pdr1 activation
We previously reported that a Zuo1 variant lacking
the ribosome-binding region (Zuo1Δ285–364) wascycloheximide
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lected and analyzed by immunoblotting for the presence of
tored by absorbance at 254nm and plotted versus the time
oring either empty vector (broken line) or vector containing
edium without (−) or with (+) cycloheximide.
21Unfolding of the C-Terminal Domain of Zuo1competent to activate Pdr1, but full-length Zuo1 was
not, even when overexpressed.7 This observation
raised the question as to whether dissociation from
the ribosome is sufficient for activation. Thus, we
made constructs encoding variants having smaller
deletions within the ribosome-binding region to test
both ribosome association using sucrose gradient
centrifugation and ability to induce PDR by plating on
medium containing the drug cycloheximide. One
variant, Zuo1Δ285–347, which has the sameN-terminal
deletion boundary as Zuo1Δ285–364 but retains 17
more residues at the C-terminal boundary, was not
ribosome associated (Fig. 1b). However, cells
expressing Zuo1Δ285–347 did not grow on drug-
containing plates, while Zuo1Δ285–364-expressing
cells grew as expected (Fig. 1c). We conclude that
dissociation of Zuo1 from the ribosome is not
sufficient to activate PDR.
Residues 348–364 inhibit the ability of Zuo1's
C-terminus to activate Pdr1
The only difference between the inactive
Zuo1Δ285–347 and the active Zuo1Δ285–364 variants is(a)
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terminal activity. We transformed wt cells with vector (pRS415
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containing an integrated PDR5-lacZ reporter and transformed
transformants each was quantified and reported as fold activati
curves of the inactive Zuo1348–433 fragment (blue) and the part
(c) 2D 15N–1H HSQC spectra of Zuo1348–433 and Zuo1358–433. (
bundle formed by the C-terminal 86 residues of Zuo1 (348–433
C-terminal activity, are shown in green.the presence of 17 residues (348–364) in the former.
Zuo1365–433, the region immediately C-terminal to
these 17 residues, is sufficient to activate Pdr1.
Therefore, we reasoned that the inactivity of
Zuo1Δ285–347 might be due to an inhibitory effect of
these 17 residues. To test this idea, we created a
construct encoding a tandem affinity purification
(TAP)-tagged fusion analogous to TAP-Zuo1365–433,
which we previously reported to be competent
to induce PDR, that included these 17 residues
(TAP-Zuo1348–433). Unlike cells expressing TAP-
Zuo1365–433, cells expressing the longer TAP-
Zuo1348–433 fusion showed no observable drug
resistance (Fig. 2a and Supplementary Fig. 1a). We
also assessed the ability of the TAP-Zuo1 fusions to
activate the promoter of a Pdr1 target gene, PDR5,
using a PDR5-lacZ fusion. Results were consistent
with the drug resistance test. Cells expressing TAP-
Zuo1365–433 had 3.2-fold higher levels of β-galacto-
sidase than control cells expressing only the TAP tag,
but the TAP-Zuo1348–433 fusion showed no activity
above this background control level (Fig. 2a). Since
our results were consistent with an inhibitory role for
residues 348–364, we also made an intermediate(b)
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with the indicated plasmids. The average activity of three
on over cells expressing TAP alone. (b) CD thermal melting
ially active Zuo1358–433 fragment (red) collected at 222nm.
d) Ribbon diagram of the solution structure of the four-helix
), referred to as the CTD. Residues 348–364, which inhibit
Table 1. NMRand refinement statistics for the 20 Zuo1348–433
conformers
Experimental constraints
Distance constraints
Long (|i− j|N5) 318
Medium (1b |i− j|≤5) 463
Sequential (|i− j|=1) 272
Intraresidue (i= j) 418
Total 1471
Dihedral angle constraints (φ and ψ) 148
Average atomic RMSD to the mean structure (Å)
(residues 349–433)
Backbone (Cα, C′, N) 0.44±0.08
Heavy atoms 0.87±0.06
Deviations from idealized covalent geometry
Bond lengths (Å) 0.014
Torsion angles (°) 1.2
Constraint violations
NOE distance: NN0.3Å 0.00±0.00
NOE distance: RMSD (Å) 0.021±0.001
Torsion angle violations: NN5° 0.00±0.00
Torsion angle violations: RMSD (°) 0.456±0.062
WHATCHECK quality indicators
Z-score 2.90±0.14
RMS Z-score
Bond lengths (Å) 0.62±0.02
Bond angles (°) 0.58±0.03
Bumps 0.00±0.00
Lennard-Jones energy (kJ/mol) −1694±72
Ramachandran statistics (% of all residues)
Most favored 91.9±1.5
Additionally allowed 6.6±1.5
Generously allowed 0±0
Disallowed 1.5±0.6
22 Unfolding of the C-Terminal Domain of Zuo1construct that encoded TAP-Zuo1358–433. TAP-
Zuo1358–433-expressing cells grew in the presence
of cycloheximide but more slowly than those ex-
pressing TAP-Zuo1365–433 (Fig. 2a and Supplemen-
tary Fig. 1a), suggesting partial inhibition of activity.
Expression from the PDR5 promoter was also
intermediate, with TAP-Zuo1358–433-expressing
cells showing 2.5-fold activation compared to the
3.2-fold activation observed with the shorter frag-
ment. These data indicate that residues 348–364
prevent activation of Pdr1 by the C-terminus of Zuo1.
Thus, sequences sufficient for both transcriptional
activation and inhibition of activity are contained
within the last 86 residues of Zuo1.
Inactive and active C-terminal fragments differ in
both stability and fold
To better understand the autoinhibitory effect of
residues 348–364, we initiated a biochemical char-
acterization of the Zuo1 C-terminal fragments. We
were unable to obtain sufficient quantities of
Zuo1365–433. Therefore, we compared the partially
active Zuo1358–433 and the inactive Zuo1348–433
fragments. The melting temperatures of Zuo1348–433
and Zuo1358–433, determined using circular dichro-
ism (CD), were substantially different, 43.5°C and
35.5 °C, respectively (Fig. 2b). Thus, removal of
N-terminal residues, which resulted in partial activity,
also resulted in a decrease in thermal stability.
Analysis of the 15N–1H heteronuclear single quan-
tum coherence (HSQC) NMR spectra of Zuo1348–433
revealed chemical shift dispersion and uniform peak
intensity consistent with a single folded domain
(Fig. 2c). The 15N–1H HSQC of the Zuo1358–433
sample, on the other hand, contained approximately
twice the number of expected peaks, suggesting the
presence of multiple structural populations. These
data indicate that C-terminal fragments of Zuo1 that
differ in their in vivo activity also differ in both
stability and fold, suggesting the possibility that a
structural transition in Zuo1's C-terminus is respon-
sible for activation of the protein's transcriptional
activity.
Autoinhibited C-terminus is a four-helix bundle
To understand the structural basis for this auto-
inhibition, we determined the solution structure of
Zuo1348–433 using an automated procedure for
iterative nuclear Overhauser enhancement (NOE)
assignment (Table 1). Zuo1348–433 folds into a left-
handed four-helix bundle (Fig. 2d and Supplemen-
tary Fig. 1b). To assure that sequences immediately
N-terminal do not substantially affect the structure of
the helical bundle, we generated two longer con-
structs extended by 13 or 32 residues. An overlay of
the 15N–1H HSQC spectra of Zuo1335–433 and
Zuo1306–433 with that of Zuo1348–433 revealed theaddition of only random-coil peaks and showed no
significant chemical shift perturbations between
these fragments (Supplementary Fig. 1c), suggest-
ing that the four-helix bundle formed by Zuo1348–433,
which we refer to as the CTD, forms whether or not
adjacent N-terminal residues are present.
Residues 348–364, which we identified as being
inhibitory to Zuo1's transcriptional activation activity,
form the first helix of the bundle (Fig. 2d, green).
Ile358, the N-terminal residue of the partially active
Zuo1358–433 fragment, is located in the center of helix I
and buried within the structure. Comparison of
the15N–1H HSQC spectrum of Zuo1358–433 with that
of the inactive CTD revealed a very similar pattern of
dispersed peaks (Fig. 2c and Supplementary Fig. 1d),
suggesting that the structured protein present in the
partially active Zuo1358–433 sample is similar in
conformation to that of the inactive CTD. The
additional peaks observed in the Zuo1358–433 sample
appear to be predominantly clustered around the
random-coil chemical shift value of ~8.2ppm, sug-
gesting that a significant population of unfolded
protein is present in the sample. These data are
consistentwith the idea that helix I is critical for stability
23Unfolding of the C-Terminal Domain of Zuo1of the CTD and that truncation of the N-terminal half of
the helix results in partial destabilization.
Unfolding of Zuo1's CTD releases autoinhibition
Our in vivo data indicate that Zuo1 is only fully
active to induce PDR in the absence of helix I, which
is integral to the CTD fold. Thus, we hypothesized that
the C-terminus of Zuo1 activates Pdr1 in an unfolded
conformation and that C-terminal sequences required
to form the helical bundle structure cause autoinhibi-
tion. To test this idea, we designed two amino acid
alterations aimed at destabilizing the fold of the
domain: (1) the buried hydrophobic residue, Leu411,
was replaced with the charged residue Arg and (2)
Lys351 and Lys355 were replaced with prolines with
the goal of preventing helix I from folding properly
(Fig. 3a). We analyzed the 15N–1H HSQC spectra of
these variants. The spectra of both Zuo1348–433 L411R
and Zuo1348–433 K351/355P showed poor peak
dispersion with the majority of peaks clustered
around the random-coil chemical shift value (Sup-
plementary Fig. 2a), indicating that these amino
acid alterations were sufficient to prevent folding of
the CTD.
To test in vivo activity, we assessed the ability of
TAP-Zuo1348–433 L411R and TAP-Zuo1348–433 K351/355P
to induce PDR. Both were competent to render cells(a)
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and Supplementary Fig. 2a. Zuo1365–433 is predicted to be unresistant to cycloheximide (Fig. 3b and Supplemen-
tary Fig. 2b). As a second in vivo test, we used a
modified yeast two-hybrid assay that we described
previously.6 In this assay, Zuo1365–433 was tethered
to GAL1 promoters by expressing it as a fusion to
the Gal4 DNA-binding domain (GBD). This fusion
auto-activated transcription in a Pdr1-dependent
manner, presumably by recruiting Pdr1, which in
turn recruits RNA polymerase. Activity was
assessed by growth on medium lacking histidine in
a test strain containing a fusion between the GAL1
promoter and the HIS3 gene. We generated a GBD
fusion construct analogous to GBD-Zuo1365–433 but
containing the entire CTD, either having or lacking
the L411R mutation that prevents folding. Cells
expressing GBD-Zuo1348–433 did not form colonies
(Fig. 3c) though expressed at expected levels
(Supplementary Fig. 2c). However, cells expressing
GBD-Zuo1348–433L411R grew as well as GBD-
Zuo1365–433-expressing cells. We also tested a
GBD fusion of Zuo1 residues 358–433, the fragment
that had a mixture of folded and unfolded confor-
mations in vitro. Cells expressing GBD-Zuo1358–433
formed colonies but grew more poorly than cells
expressing the shorter GBD-Zuo1365–433 fusion
(Fig. 3c and Supplementary Fig. 2c). Together, our
data strongly support the idea that Zuo1's C-
terminus activates Pdr1 in an unfolded conformation.cycloheximide
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24 Unfolding of the C-Terminal Domain of Zuo1TheC-terminal 13 residues of Zuo1 are necessary
and sufficient for Pdr1 activation
While our results indicate that unfolding of Zuo1's
CTD is required for activation of Pdr1 and that the C-
terminal 69 residues (365–433) are sufficient for this
activity, the residues necessary for activity were not
known. Thus, we constructed a series of truncations
to generate TAP tag fusions beginning at residues
388, 403 and 421, but all ending at C-terminal
residue 433, to test whether a smaller segment is
sufficient. All shorter C-terminal fragments tested
enabled cells to grow similarly to those expressing
TAP-Zuo1365–433 on cycloheximide-containing
plates (Fig. 4a). Also, β-galactosidase activities in
cells expressing each of the shorter C-terminal
truncations were statistically indistinguishable from
the activity observed in TAP-Zuo1365–433-expressing
cells, indicating an equivalent ability of the fusions to
activate the PDR5 promoter. These results indicate
that the C-terminal 13 residues of Zuo1 (421–433)
are sufficient to activate PDR.
We carried out two additional experiments to
determine the necessity of these 13 residues for
activation. First, to confirm that these residues are
necessary for activation in the context of the larger
Zuo1365–433 fragment, we generated a construct that
lacks the codons for these 13 residues, TAP-365
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in (a) and (b) and subjected to immunoblot analysis using rabZuo1365–420. Cells expressing TAP-Zuo1365–420 did
not form colonies on cycloheximide-containing
plates and had β-galactosidase activity similar to
the basal level found in cells expressing only the
TAP tag (Fig. 4a). Second, we constructed three
additional TAP fusions having even smaller seg-
ments of the extreme C-terminus of Zuo1, generat-
ing TAP-Zuo1425–433, TAP-Zuo1428–433 and TAP-
Zuo1430–433. None of these shorter C-terminal
fusions were able to support growth on drug-
containing plates (Fig. 4b and c). Thus, we conclude
that the 13 extreme C-terminal residues (421–433)
of Zuo1 are both necessary and sufficient for Pdr1
activation.
Residues critical for Pdr1 activation are buried
in the C-terminal helical bundle
To identify individual residues required for Pdr1
activation within the 13-residue segment identified
as sufficient, we performed alanine scanning muta-
genesis. Cells expressing either wild-type (wt) TAP-
Zuo1365–433 or TAP-Zuo1365–433 containing 1 of the
13 alanine substitutions were plated on medium
containing or lacking cycloheximide. Cells express-
ing the Leu428, Leu429, Tyr431 or Val433 substitu-
tion variants did not grow on cycloheximide-
containing plates (Fig. 5a and Supplementary Fig.eximide
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25Unfolding of the C-Terminal Domain of Zuo13a). Those expressing the Pro425 or Phe432 sub-
stitutions grew much more slowly than those
expressing the wt fusion. Alteration of only one
hydrophobic residue, Leu424, was tolerated, while
alteration of the six other residues had no obvious
effect on Pdr1 activation.
We also performed an analogous alanine scan
using the modified two-hybrid assay. The pattern of
effects of alterations in the GBD-Zuo1365–433 fusions
was very similar to that found with the TAP-Zuo1365–
433 fusions. Cells expressing GBD-Zuo1365–433 in
which any of the seven hydrophobic residues in the
extreme C-terminus (Leu424, Pro425, Leu428,
Leu429, Tyr431, Phe432 or Val433) were altered
showed no growth on selective medium, indicating a
failure to activate the Gal4-inducible reporters
(Fig. 5a and Supplementary Fig. 3b). Alteration of
any of the polar or charged residues, on the other
hand, had no effect on activity. Thus, we conclude
that hydrophobic residues within the extreme C-
terminus play critical roles in PDR induction.
Examination of the position of these critical
hydrophobic residues within the helical bundle
structure revealed, as expected, that these residues(a) cycloheximide
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core of the domain (Fig. 5b). Thus, we hypothesized
that residues required for PDR activation also play
important roles in domain structure. To test this idea,
we generated a construct to express the CTD of
Zuo1 lacking the three most C-terminal residues
(Tyr431, Phe432 and Val433), as these residues are
not only important for activity but also deeply buried
and particularly well constrained within the hydro-
phobic core of the domain (Fig. 5c). The 15N–1H
HSQC of this variant, Zuo1348–430, showed poor
peak dispersion with the majority of peaks centered
around the random-coil chemical shift value, consis-
tent with the protein being in an unfolded conforma-
tion (Fig. 5d), confirming the importance of these
residues in maintaining domain structure.
Specificity of Zuo1's hydrophobic C-terminus in
Pdr1-dependent transcriptional activation
The sufficiency of such a short segment of Zuo1
for PDR activation, coupled with the importance of
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Fig. 6. Specificity of Zuo1's hydrophobic C-terminus in Pdr1-dependent transcriptional activation. (Left) We transformed
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26 Unfolding of the C-Terminal Domain of Zuo1peptides have been found to act as general
transcriptional activators when tethered to DNA.
Thus, we compared the transcription activation
potential of the Zuo1 peptide with two other
hydrophobic peptides, referred to as P201 (YLLPT-
CIP) and P223 (YLLPFLPY), which were originally
selected for their ability to activate transcription from
the GAL1 promoter when fused to GBD.19 Unlike
cells expressing only GBD, cells expressing any one
of the three peptide fusions, GBD-Zuo1421–433, GBD-
P201 and GBD-P233, grew on plates lacking
histidine, indicating activation of the GAL1-HIS3
reporter (Fig. 6, left). We next tested the ability of the
fusions to activate transcription in the absence of
Pdr1. As expected, Δpdr1 cells expressing GBD-
Zuo1421–433 did not grow in the absence of histidine.
GBD-P201 and GBD-P223, on the other hand,
activated GAL1-HIS3 even in the absence of Pdr1.
As a second test of specificity, we asked whether
cells expressing TAP tag fusions of peptides P201
and P223 could, like Zuo1421–433, activate PDR
when not tethered to DNA. Unlike cells expressing
TAP-Zuo1421–433, no detectable drug resistance wasZuo1 Z
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Fig. 7. Unfolding of the CTD results in dissociation of Zuo1 fr
containing DNA encoding Zuo1 or variants of Zuo1 with alterat
endogenous ZUO1 promoter. Lysates of cells harboring the
gradients, and fractions were collected and analyzed by immun
of ribosomal subunits was monitored by absorbance at 254nmobserved for cells expressing TAP-P201 or TAP-
P223, whether or not Pdr1 was present (Fig. 6, right;
Supplementary Fig. 4). Together, these data indicate
that, although activation of Pdr1 by Zuo1 requires a
short hydrophobic peptide, the observed transcrip-
tional activation is distinct from the general tran-
scriptional properties observed previously for
hydrophobic peptides tethered to DNA.
C-terminal unfolding results in dissociation of
Zuo1 from the ribosome
The results discussed above indicate that both
dissociation of Zuo1 from the ribosome and unfolding
of the CTD are necessary for the specific activation of
Pdr1. To assess the effect of unfolding of the CTD on
ribosome association, we tested the migration in
sucrose gradients of two Zuo1 variants having amino
acid alterations that cause unfolding of the CTD,
Zuo1L411R and Zuo1Δ431–433. Unlike wt Zuo1, neither
variant co-migrated with ribosomes during centrifu-
gation (Fig. 7). Rather, both remained at the top of the
gradient. The lack of ribosome association of theseuo1L411R Zuo1Δ431-433
soluble
80S 80S
polysomes polysomes
A 2
54
40S
60S
S
60S
om the ribosome. Δzuo1 cells were transformed with vector
ions that result in unfolding of the CTD under control of the
indicated plasmids were separated on 5–50% sucrose
oblotting for the presence of Zuo1 and Rpl3. The migration
and plotted versus the time course of fraction collection.
27Unfolding of the C-Terminal Domain of Zuo1variants is consistent with a folded CTD being
required for association of Zuo1 with the ribosome.Discussion
The data presented here indicate that unfolding of
the extremeCTDof Zuo1 results in both its dissociation
from the ribosome and release of autoinhibition
unleashing its ability to specifically activate the Pdr1
TF. This dual effect of unfolding of the CTD suggests a
pathway of communication between the cytosolic
translational apparatus and the nuclear transcriptional
machinery.
The extreme C-terminal 13 residues of Zuo1 are
necessary and sufficient for activation of Pdr1, with
hydrophobic residues playing critical roles in this
activation. Although short hydrophobic peptides have
been identified as recruiters of the general transcrip-
tion machinery,20,21 Zuo1's C-terminus activates
transcription specifically through Pdr1. This specificity
is consistent with previously reported microarray data
demonstrating that the PDR regulon is themajor class
of genes upregulated by the C-terminus of Zuo1.6
Positive two-hybrid interaction analyses indicate that
the interaction between Zuo1 and Pdr1 is direct,6
pointing to a model in which Zuo1's C-terminal
hydrophobic peptide interacts directly with Pdr1,
leading to mobilization of Pdr1's activation domain
that is thought to be inhibited by its central regulatory
region.10,22 Such amode of activation is analogous to
the direct binding of xenobiotics observed for both
yeast and mammalian TFs in PDR.9,23,24 It should be
noted, however, that Pdr1 activation may be more
complex, as Zuo1 forms a very stable heterodimer
with the atypical Hsp70 Ssz1,25 often called the
ribosome-associated complex. Ssz1, when not ribo-
some associated, also activates Pdr1.26 Thus, it is
likely that Zuo1 and Ssz1 act in concert as a complex
in the natural environment to activate Pdr1.
For Zuo1 to activate Pdr1, its C-terminus must be
unfolded, as hydrophobic residues in the extreme C-
terminus critical for activation of Pdr1 are seques-
tered within a four-helix bundle formed by the C-
terminal 86 residues and are thus inaccessible for
intermolecular interactions in the folded conforma-
tion. The positive correlation between unfolding and
transcriptional activation we observed points to a
scenario in which Zuo1's activity in Pdr1-dependent
transcriptional activation is regulated by autoinhibi-
tion conferred by the CTD structure, with activity
being induced upon a folding:unfolding transition of
its helical bundle domain. Although, to our knowl-
edge, there are few, if any, examples of unfolding as
a requirement for a protein to activate a TF, unfolding
as a mode of positive regulation certainly has
precedents. Perhaps best understood is N-WASP,
which, in its structured form, sequesters key hydro-
phobic residues in its C-terminal VCA regionrequired for actin polymerization.27 Cdc42 binding
releases this autoinhibition by disrupting the folded
structure of a helical GTPase-binding domain.
Unfolding of this domain releases the cofilin homol-
ogy motif and allows the VCA region to activate the
Arp2/3 complex.
Previous work identified an 80-residue charged
region in Zuo1 (285–364) required for ribosome
binding.3,28 The structural analysis reported here
demonstrates that residues at the C-terminal bound-
ary of this ribosome-binding region are necessary for
formation of the C-terminal helical bundle. More
experiments will be required to understand the
molecular interactions responsible for Zuo1's asso-
ciation with the ribosome, both in terms of protein:
RNA and protein:protein contacts, and the intermo-
lecular effects of unfolding of the CTD. However,
even without this information in hand, a plausible
hypothesis is that the two requisite steps for Pdr1
activation, ribosome dissociation and unfolding of
the CTD to expose critical hydrophobic residues, are
coupled, as alterations that promote unfolding of
Zuo1's CTD also result in dissociation of Zuo1 from
the ribosome. Thus, a shift in the equilibrium of the
CTD to an unfolded conformation likely increases
the amount of soluble Zuo1 free to activate Pdr1.
The idea that Zuo1's CTD is active in an unfolded
conformation raises the question of how the auto-
inhibited structure gains access to the unfolded state
that results in both ribosome dissociation and
exposure of residues required for Pdr1 activation.
Depending on the free energy of folding (ΔGfold), a
significant population of unfolded CTD may exist in
equilibrium with the folded structure, as observed by
two-dimensional (2D) NMR for the Zuo1358–433
construct (Fig. 2c). Based on the NMR spectra and
CDmeasurements of thermal unfolding, we estimate
that the Zuo1348–433 and Zuo1358–433 C-terminal
fragments fold with relatively small margins of
stability, with ΔGfold~−2 and −1kcal/mol, respec-
tively. These estimates suggest that, in the absence
of other stabilizing or destabilizing interactions,
roughly 4% of the CTD would be unfolded, a
percentage consistent with observations that the
vast majority of Zuo1 is ribosome associated under
typical laboratory conditions. When Zuo1 is bound to
the ribosome and the majority of the CTD is folded,
we predict that the Pdr1-activating epitope would be
exposed at low levels by a basal level of equilibrium
unfolding. Such a low amount of the unfolded,
ribosome-free form is likely insufficient to induce
Pdr1 activation. However, a binding partner that
recognizes a distinct segment of the unfolded CTD
would shift the equilibrium toward the unfolded state,
with the net effect of destabilizing the autoinhibitory
conformation and promoting Pdr1 activation.
In a broader physiological context, the relationship
among Zuo1 (and Ssz1), the ribosome and cellular
signaling is intriguing. The translational apparatus
28 Unfolding of the C-Terminal Domain of Zuo1has been repeatedly linked to growth control and cell
cycle regulation.29,30 Indeed, activation of Pdr1
leads to premature growth arrest as cells transition
from preferred to non-preferred carbon sources,
presumably due to sensing by neighboring cells of
metabolites exported by induced transporters. It is
worth noting that transcriptional regulatory functions
of ribosome-associated chaperones may extend
beyond Zuo1:Ssz1. Components of the nascent
chain-associated complex have been reported to
function as transcriptional coactivators.31,32 The
work presented here is a start in unraveling the
complex regulatory pathway for ribosome-associat-
ed complex components. Further work will be
necessary to understand the dynamics of the
interaction of these chaperones with the ribosome,
including the identification of factors that affect the
folding:unfolding equilibrium of Zuo1's CTD and the
balance between their function in protein folding at
the ribosome and their regulatory roles in extra-
ribosomal transcriptional activation.Materials and Methods
Yeast strains and plasmids
Yeast strains used were isogenic with DS10 and contain
the following mutations: his3-11,15 leu2-3,112 lys1 lys2
trp1Δ ura3-52. Δzuo1::HIS31 and Δpdr1::TRP16 have
been described previously. A strain containing an inte-
grated PDR5-lacZ reporter was created by digesting the
pTH120 plasmid containing PDR5-lacZ::HIS326 with StuI
and transforming the resulting fragment into DS10 wt or
Δpdr1::TRP1 to direct integration at the PDR5 locus. TAP
and TAP-Zuo1365–433 plasmids were described
previously.6 Additional plasmids created for this study
are described in Supplementary Table 1.Assays for PDR induction
To assay drug resistance, we subjected approximately
equal numbers of cells to 10-fold serial dilutions and spotted
them on selective minimal glucose medium containing 0,
0.7 or 1μg/ml cycloheximide. Plates were incubated at
30°C for 2–3days before photographing. β-Galactosidase
assays were performed as previously described7 using
strains containing an integrated PDR5-lacZ reporter. A
minimum of three independent transformants was tested,
and the average activity was determined.
Analysis of ribosome association
Δzuo1 cells containing the indicated plasmids were
grown to an OD600 between 0.5 and 0.8 in selective
minimal medium, treated with 100μg/ml cycloheximide
and harvested by centrifugation at 4 °C. Cells were
resuspended in 20mM Tris–HCl (pH7.5), 50mM KCl and
5mM MgCl2 buffer containing 0.1mM phenylmethylsulfo-
nyl fluoride and 1.5mM pepstatin and treated with RNasin(Promega) at a dilution of 1:1000. Yeast lysates were
prepared by bead beating for 5min and clarified by
centrifugation at 14,000rpm for 10min. To fractionate
polysomes, we applied approximately 10 OD260 units of
lysate to the top of a 4-ml 5–50% sucrose gradient in the
resuspension buffer and centrifuged for 80min at
45,000rpm at 4°C in a SW50.1 Ti rotor (Beckman).
Gradients were monitored for absorbance at 254nm to
detect monosomes and polysomes. Fractions were
precipitated with 10% trichloroacetic acid, separated by
SDS-PAGE and subjected to immunoblotting.
Modified yeast two-hybrid assay
Strains PJ69 and PJ69 Δpdr1::TRP1, the GBD and GBD-
Zuo1365–433 plasmids and yeast two-hybrid methods were
described previously.6,33 Additional plasmids generated for
this study are described in Supplementary Table 1.
Modified yeast two-hybrid assay was carried out by
detecting auto-activation of GAL1-HIS3 and/or Gal2-ADE2
reporters of PJ69 wt or Δpdr1 cells by monitoring growth on
minimal medium lacking uracil for plasmid selection and
either histidine and adenine or histidine and containing
2mM 3-aminotriazole, as described previously.6 Plates
were incubated for 2–3days at 30°C before photographing.
Protein expression and purification
We expressed 8× His-tagged Zuo1 C-terminal fragments
in Escherichia coli BL21[pREP4] cells from pQE308HT34-
based plasmids described in Supplementary Table 1. Cells
were grown at 37°C to an OD600≈0.8 in LB medium
containing 150μg/ml ampicillin and 50μg/ml kanamycin;
expression was induced by the addition of isopropyl β-D-
thiogalactopyranoside to a final concentration of 1mM, and
cells were grown for an additional 3h at 15°C following
induction. Isotopically labeled proteins were prepared for
NMR by growing cultures in M9 medium containing [15N]
ammonium chloride and/or [13C]glucose as the sole
nitrogen and carbon sources, respectively. Cells harvested
from a 1-l culture were resuspended in 50mM sodium
phosphate (pH7.4), 300mM NaCl, 40mM imidazole and
0.1% (w/v) 2-mercaptoethanol buffer containing an ethyle-
nediaminetetraacetic-acid-free Complete Protease Inhibi-
tor Cocktail tablet (Roche). Cells were lysed using a French
pressure cell, and protein was purified at 4°C by immobi-
lizedmetal-ion affinity chromatography using Ni-Sepharose
6 Fast Flow resin (GEHealthcare) according to a previously
published protocol.35 Following purification, the protein
solutions were dialyzed 2× into 2 l of 20mM sodium
phosphate (pH6.5), 50mM NaCl and 1mM dithiothreitol.
Dialyzed protein was concentrated to approximately 500μl
for analysis by NMR, and the purity and identity were
verified by SDS-PAGE and/or mass spectrometry.
CD spectroscopy
Samples of Zuo1348–433 andZuo1358–433were preparedat
a concentration of 20μM in buffer containing 20mM sodium
phosphate (pH6.5) and 50mM NaCl. Thermal denaturation
experiments were performed in a 1-mm cuvette, and the
ellipticity wasmonitored at 222nmover a temperature range
of 10–70°C. Thermal denaturation curves were analyzed by
29Unfolding of the C-Terminal Domain of Zuo1nonlinear least-squares fitting as previously described to
determine the melting temperature.36
NMR spectroscopy
NMR samples were prepared in buffer containing 20mM
sodium phosphate (pH6.5), 50mM sodium chloride, 1mM
dithiothreitol and 5–10% 2H2O. All 2D
15N–1H HSQC
spectra were acquired at 20 or 25°C on a Bruker 500- or
600-MHz spectrometer equipped with a triple-resonance
CryoProbe™ and processed with NMRPipe software.37
The Zuo1348–433 sample used for structure determination
was prepared in the identical buffer at a concentration of
1.2mM. All structural data were acquired at 10°C using a
field strength of 600MHz. Backbone 1H, 15N and 13C
chemical shift assignments for Zuo1348–433 were obtained
automatically as previously described using peak lists from
15N–1H HSQC, HNCO, HN(CO)CA, HN(CO)CACB,
HNCA, HNCACB, HN(CA)CO and CC(CO)NH.38 Side-
chain assignments were completed manually from three-
dimensional HBHACONH, HCCONH, HCCH total correla-
tion spectroscopy and 13C(aromatic)-edited NOE spec-
troscopy (NOESY)–HSQC spectra. Chemical shift
assignments were N99%complete for Zuo1348–433. Hetero-
nuclear NOE values were measured from an interleaved
pair of 2D 15N–1H sensitivity-enhanced correlation spectra
recorded with and without a 5-s proton saturation period.
Structure calculation and analysis
The Zuo1348–433 structure was calculated using distance
constraints obtained from three-dimensional 15N-edited
NOESY–HSQC and 13C-edited NOESY–HSQC (τmix=
80ms). Backbone φ and ψ dihedral angle constraints
were generated from secondary shifts of the 1H, 13Cα,
13Cβ, 13C′ and 15N nuclei using the program TALOS.39
Structure calculations were performed using the torsion
angle dynamics program CYANA40 followed by iterative
rounds of manual refinement to eliminate constraint
violations. Of the 100 CYANA structures calculated, the
20 conformers with the lowest target function were
subjected to a molecular dynamics protocol in explicit
solvent41 using Xplor-NIH.42 PyMOL (Schrödinger, LLC)
was used to generate all structure images.
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